Product · #20 of 27 · multi-symptom (single active)
Equelle Menopause Multi-Symptom Relief
Tablet from Equelle, made by Bonafide / Pharmavite (Otsuka). Daily serving: 2 tablets.
Last updated · Price and ratings checked Nov 19, 2026
In short: Equelle Menopause Multi-Symptom Relief scores 47.4/100 in our ranking (#20 of 27). It costs $1.40 a day at the regular price. Evidence: S-equol 10 mg; own trials, one without placebo, sponsor-funded; best ingredient grade C (S-equol). No NSF registry listing was confirmed.
Pros
- Has its own published product trials (2 in our library); see who funded them below.
- Evidence: S-equol 10 mg; own trials, one without placebo, sponsor-funded.
Cons
- No NSF registry listing confirmed.
Flags
Watchdog complaint
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| S-equol (from fermented soy germ) | 10 mg | S-equol C |
| Calcium | 240 mg | Vitamin D & calcium B |
Label read from the official product image.
Evidence
Our evidence score: 25/40, because: S-equol 10 mg; own trials, one without placebo, sponsor-funded.
Product-level research: Equelle site also cites unpublished 'Data on File 1811 Study Report'; sleep claim footnoted as 'significant vs baseline and not placebo'. Evidence grade for the branded product: C C.
Ingredient evidence
- S-equol C (10 mg here)
S-equol is a soy-derived compound (the active in Equelle) studied for occasional hot flashes and muscle aches associated with menopause*. Results are mixed, and the key trials were sponsored by companies behind the ingredient or product. The Menopause Society 2023: Not recommended (Level II) – mixed evidence. - Vitamin D & calcium B (240 mg here)
Calcium and vitamin D support bone health*. Large trials, including the Women's Health Initiative, show a small effect on bone density, and effects on fractures are mixed. The Menopause Society 2023: Not part of VMS statement.
Studies
Trials of this product
-
A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency.
The only US hot-flash trial of S-equol compared different doses with soy isoflavones, with no placebo group. All groups improved similarly; higher doses did slightly better. It was run by Pharmavite, which makes Equelle.
- Who
- 102 US postmenopausal women
- Dose
- S-equol 10, 20 or 40 mg/day vs soy isoflavones (no placebo)
- Duration
- 8 weeks
- Result
- Similar hot-flash reductions at week 8; 40 mg beat isoflavones on cumulative analysis; 10–20 mg better for muscle/joint pain.
- Funding
- Pharmavite LLC (Equelle maker) – lead author employee. Industry-linked
-
A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women.
160 Japanese women who could not make equol themselves took 10 mg S-equol or placebo for 12 weeks. Hot flashes fell about 59% vs 35% on placebo. The ingredient's maker ran the research, and Japanese women tend to have milder hot flashes than US women.
- Who
- 160 Japanese equol non-producers (126 completed)
- Dose
- natural S-equol 10 mg/day
- Duration
- 12 weeks
- Result
- Hot flushes -58.7% vs -34.5% placebo (P=.009); less neck/shoulder stiffness.
- Funding
- Otsuka Pharmaceutical (developer of the S-equol ingredient used in Equelle). Industry-linked
Studies on its ingredients (1)
-
Equol Decreases Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
An analysis of 6 trials found S-equol lowered hot-flash scores overall, but 2 of the 5 pooled trials found no benefit and most trials were small.
- Who
- 6 RCTs, 779 women
- Dose
- S-equol or isoflavones in equol producers
- Duration
- various
- Result
- Pooled benefit on hot-flash scores; 3 of 5 trials positive, 2 null.
- Funding
- Academic (Korea); not stated as industry funded. Independent / academic
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $42.00 (60 units, 30 days at label dose) |
|---|---|
| Cost per day | $1.40 |
| Subscription | 30-day $39.90/mo; 90-day $111 ($37/mo) |
| Price notes | Amazon B0FTTCLPB2 60 ct $44.99 |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: ★ 4.2 from 314 ratings on Amazon (checked Nov 19, 2026)
Brand site: ★ 4.2, 2,717 reviews on equelle.com (checked Nov 19, 2026). Brand-site reviews are moderated by the brand.
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “hormone-free* (contains plant isoflavone metabolite)” Brand claim
- “clinically studied” Brand claim
Registry check: NSF/ANSI 173: not found
Who's behind it
| Brand | Equelle |
|---|---|
| Owner / company | Bonafide Health, LLC dba Equelle (Harrison, NY) – Pharmavite LLC. |
| Founders | Not stated on the pages we read. |
| Where it's made | not stated. |
| Medical advisors named | None named on the pages we read. |
| Source | equelle.com |
Flags & safety
Legal, regulatory and quality flags
- TINA.org complaint to FTC & FDA (Oct 2024) alleging deceptive marketing of Equelle (Pharmavite). truthinadvertising.org
Ingredient safety notes
- S-equol: Soy-derived; avoid with soy allergy. Breast-cancer-history safety not established for concentrated isoflavone products. US trial lacked placebo; most data in Japanese women.
- Vitamin D & calcium: Kidney stones increased (WHI HR 1.17). WHI long-term follow-up: CVD mortality HR 1.06, cancer mortality HR 0.93.
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.